TRINETRA › Sectors › Healthcare
Venus Remedies Limited (VENUSREM) — share price, P/E and fundamentals
Venus Remedies Limited (NSE: VENUSREM) closed at ₹1,238.60 on 30 Oct 2026, +174.1% over one year, against a 52-week range of ₹432.10 – ₹2,044.30.
In the quarter ended 30 Sept 2026 (consolidated, filed 26 Oct 2026) it reported revenue of ₹219 cr and net profit of ₹26 cr, a 11.7% net margin; revenue grew 13.5% and profit grew 26.3% year on year.
On four consecutive filed quarters its trailing P/E is 13.6; since 26 May 2025 its own P/E has ranged from 10.7 to 25.3 (median 16.4), and today's reading is higher than 26% of those 354 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 14.6%, ROCE 18.3%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 39% of 64 sector peers; PBT margin higher than 34% of 64 sector peers; ROE higher than 53% of 64 sector peers.
Key figures
| Last close | ₹1,238.60 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -23.8% / +30.4% / +174.1% |
| 52-week low – high | ₹432.10 – ₹2,044.30 |
| Market capitalisation | ₹1,656 cr |
| Trailing P/E | 13.6 |
| Price / book | 2.35 |
| EV / EBITDA | 8.7 |
| Earnings yield | 7.4% |
| TTM EPS | ₹91.02 |
| TTM net profit | ₹122 cr |
| Quarter revenue | ₹219 cr |
| Quarter net profit | ₹26 cr |
| Net margin | 11.7% |
| Revenue growth (YoY) | +13.5% |
| Profit growth (YoY) | +26.3% |
| Return on equity | 14.6% |
| ROCE | 18.3% |
| Debt / equity | 0.00 |
| Current ratio | 3.31 |
| Free cash flow | ₹0 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹4.6 cr |
Against Healthcare peers
| Metric | VENUSREM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.73 | 12.89 | 39 |
| PBT margin | 15.30 | 17.68 | 34 |
| ROE | 14.56 | 13.87 | 53 |
| ROCE | 18.34 | 17.26 | 59 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 0.10 | -0.87 | 53 |
| Cash conversion | 0.54 | 1.25 | 15 |
| Trailing P/E | 13.61 | 43.26 | 3 |
Questions
What is the P/E ratio of Venus Remedies Limited?
Venus Remedies Limited's trailing P/E is 13.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 26 May 2025 its P/E has ranged 10.7–25.3.
What were Venus Remedies Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Venus Remedies Limited reported revenue of ₹219 cr and net profit of ₹26 cr (consolidated), filed with the exchange on 26 Oct 2026.
What is Venus Remedies Limited's ROE?
Return on equity is 14.6% based on the balance sheet dated 30 Sept 2026.
Does Venus Remedies Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is VENUSREM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, VENUSREM traded between ₹432.10 and ₹2,044.30.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.